While economic evaluations remain the purview of national bodies, the JCA now mirrors the centralised approach of the ...

Anti-amyloid antibody Leqembi (lecanemab) made its EU debut in Austria yesterday and will be introduced in Germany on Monday ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 ...

Pharma commercialisation services provider EVERSANA (pharmaphorum's parent company) has acquired Waltz Health, a Chicago ...

An unusual study presented at the European Society of Cardiology (ESC) congress in Madrid today has found that treating heart ...

Notably, the Pfizer approval covers those with an underlying condition starting at age five. Under the emergency use ...

Armed with new survival data from the monarchE trial of CDK4/6 inhibitor Verzenio, Eli Lilly looks set to cement the drug's ...

The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which ...

Telehealth company Ro has a new spokesperson for its booming GLP-1 business: Serena Williams, the 23-time Grand Slam champion ...

Current therapies for gMG include AstraZeneca/Alexion's complement C5 inhibitor Ultomiris (ravulizumab), which needs to be ...

To begin, let’s consider a cornerstone of European patent law: Article 53 (c) of the European Patent Convention (EPC). This ...

This includes exploring the use of complement-mediators as combination therapies, discovering innovative indications where ...